207 related articles for article (PubMed ID: 35033181)
1. Direct comparison of different therapeutic cell types susceptibility to inflammatory cytokines associated with COVID-19 acute lung injury.
Vaka R; Khan S; Ye B; Risha Y; Parent S; Courtman D; Stewart DJ; Davis DR
Stem Cell Res Ther; 2022 Jan; 13(1):20. PubMed ID: 35033181
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19.
Gupta A; Shivaji K; Kadam S; Gupta M; Rodriguez HC; Potty AG; El-Amin SF; Maffulli N
Expert Opin Biol Ther; 2021 Dec; 21(12):1551-1560. PubMed ID: 33886388
[No Abstract] [Full Text] [Related]
3. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
Grumet M; Sherman J; Dorf BS
Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Placental Mesenchymal Stromal Cell Secretome from Two- and Three-Dimensional Cell Cultures Promotes Survival and Regeneration in Acute Lung Injury Model in Mice.
Kudinov VA; Artyushev RI; Zurina IM; Zorina ES; Lapshin RD; Snopova LB; Mukhina IV; Saburina IN
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408778
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
6. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
[TBL] [Abstract][Full Text] [Related]
7. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
[TBL] [Abstract][Full Text] [Related]
8. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis of mesenchymal stromal/stem cells as strategical means for the treatment of COVID-19.
Taufiq H; Shaik Fakiruddin K; Muzaffar U; Lim MN; Rusli S; Kamaluddin NR; Esa E; Abdullah S
Ther Adv Respir Dis; 2023; 17():17534666231158276. PubMed ID: 37128999
[TBL] [Abstract][Full Text] [Related]
10. Stem Cell Extracellular Vesicles as Anti-SARS-CoV-2 Immunomodulatory Therapeutics: A Systematic Review of Clinical and Preclinical Studies.
Ahmed SH; AlMoslemany MA; Witwer KW; Tehamy AG; El-Badri N
Stem Cell Rev Rep; 2024 May; 20(4):900-930. PubMed ID: 38393666
[TBL] [Abstract][Full Text] [Related]
11. Specific cytokines in the inflammatory cytokine storm of patients with COVID-19-associated acute respiratory distress syndrome and extrapulmonary multiple-organ dysfunction.
Wang J; Yang X; Li Y; Huang JA; Jiang J; Su N
Virol J; 2021 Jun; 18(1):117. PubMed ID: 34088317
[TBL] [Abstract][Full Text] [Related]
12. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.
Russo E; Corrao S; Di Gaudio F; Alberti G; Caprnda M; Kubatka P; Kruzliak P; Miceli V; Conaldi PG; Borlongan CV; La Rocca G
Cells; 2023 Jun; 12(12):. PubMed ID: 37371134
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
[TBL] [Abstract][Full Text] [Related]
14. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S; Abdelalim EM
Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
[TBL] [Abstract][Full Text] [Related]
15. Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome-An Observational Pilot Study.
Notz Q; Schmalzing M; Wedekink F; Schlesinger T; Gernert M; Herrmann J; Sorger L; Weismann D; Schmid B; Sitter M; Schlegel N; Kranke P; Wischhusen J; Meybohm P; Lotz C
Front Immunol; 2020; 11():581338. PubMed ID: 33123167
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells as a therapeutic intervention for COVID-19: a living systematic review and meta-analysis protocol.
Kirkham AM; Monaghan M; Bailey AJM; Shorr R; Lalu MM; Fergusson DA; Allan DS
Syst Rev; 2021 Sep; 10(1):249. PubMed ID: 34526123
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
Wang W; Lei W; Jiang L; Gao S; Hu S; Zhao ZG; Niu CY; Zhao ZA
J Transl Med; 2021 May; 19(1):198. PubMed ID: 33971907
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: a successful phase 1, control-placebo group, clinical trial.
Kaffash Farkhad N; Sedaghat A; Reihani H; Adhami Moghadam A; Bagheri Moghadam A; Khadem Ghaebi N; Khodadoust MA; Ganjali R; Tafreshian AR; Tavakol-Afshari J
Stem Cell Res Ther; 2022 Jun; 13(1):283. PubMed ID: 35765103
[TBL] [Abstract][Full Text] [Related]
19. The Promise of Mesenchymal Stem Cells Therapy for Acute Respiratory Distress Syndrome Caused by COVID-19.
Gu J; Zhao Q; Han Z; Han Z
Curr Stem Cell Res Ther; 2021; 16(3):277-285. PubMed ID: 32729428
[TBL] [Abstract][Full Text] [Related]
20. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
